CompletedNot Applicable

Cathelicidin LL-37 Relation to Potentially Malignant Lesions

Egypt45 participantsStarted 2023-07-01

Plain-language summary

LL-37 appears to have a potential role in potentially malignant lesions (OLP \& leukoplakia). The remarkable diagnostic accuracy of salivary LL-37 in differentiating potentially malignant lesion and healthy control could confirm its utilization as an innovative marker to early diagnose potentially malignant lesions. Salivary LL-37 being non-invasive accurate marker could be as a chair-side diagnostic method that detect potentially malignant lesions.

Who can participate

Age range30 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Both genders with age range 30 - 70 years. * Patients agreed to sign a written consent after understanding the nature of the study. * Clinically diagnosed and histologically confirmed as having oral potentially malignant lesions mainly atrophic/erosive oral lichen planus and oral leukoplakia. Exclusion Criteria: * Systemic diseases as well as pregnant or lactating females. * Patients currently taking corticosteroids, immunosuppressives drugs, contraceptive pills, or antibiotics. * Patients are diagnosed with any other oral lesions other than oral lichen planus and oral leukoplakia. * Vulnerable subjects as prisoners, or mentally disabled.

What they're measuring

Cathelicidin LL-37 level in salivary samples from all participants mesured using ELISA

Timeframe: level of LL-37 is measured after the completion of all sample collection carried at the 1 day of enrollement of subjects in the investigation after diagnosis confirmation

Trial details

NCT IDNCT06219330

SponsorFayoum University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-10-30

View on ClinicalTrials.gov More Oral Potentially Malignant Lesions trials